Phaseline

Targets › CD25

CD25: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2032.

Open in Phaseline: the race on CD25, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PolTREGex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)
Ex vivo expanded regulatory T cell therapy
CD4, CD25, IL2RAPhase 2Presymptomatic Diabetes Type 1 (Stage 1)Dec 2032

Conditions

Presymptomatic Diabetes Type 1 (Stage 1) (1)

Modalities

mixed (1)

Companies

PolTREG (1)

Related targets

CD4 (1) IL2RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.